// App-Quantinova.ai

e12019 : Real-life effectiveness of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients: An Italian observational study.

Researchers

Presenter

  • Alessandra Fabi

Principal Investigators

  • Katia Cannita

  • Gianluigi Ferretti

  • Mariangela Ciccarese

  • Grazia Arpino

  • Filippo Montemurro

  • Nicla Maria La Verde

  • Daniele Giulio Generali

  • Giuseppina Scandurra

  • Gianfranco Filippelli

  • Michelangelo Russillo

  • Ida Paris

  • Simonetta Stani

  • Agnese Fabbri

  • Mauro Minelli

  • Francesco Cognetti

  • Diana Giannarelli

Medical Centers

  • Division of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy

  • L'Aquila Hospital, L'aquila, Italy

  • REGINA ELENA NATIONAL CANCER INSTITUTE, Rome, Italy

  • Vito Fazzi Hospital - Lecce, Copertino, Italy

  • University of Naples Federico II, Naples, Italy

  • Fondazione del Piemonte per l'Oncologia, Candiolo Cancer Center, Candiolo, Italy

  • AO Fatebenefratelli e Oftalmico, Milan, Italy

  • Istituti Osp.di Cremona, Cremona, Italy

  • Oncological Hospital, Catania, Italy

  • Ospedale S. Francesco di Paola, Paola, Italy

  • Oncological Hospital, Lucca, Italy

  • Catholic University of the Sacred Heart, Rome, Italy

  • Saint Spirit Hospital, Rome, Italy

  • Bel Colle Hospital, Viterbo, Italy

  • Saint Joanne Hospital, Rome, Italy

  • Regina Elena National Cancer Institute, Rome, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved